Business
PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. “In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter,” said Larry Wood, Chief Exe
About this update from Procept Biorobotics Corporation
[{"type":"image","alt":"PROCEPT BioRobotics","displaySize":"","headline":null,"caption":"PROCEPT BioRobotics","className":"","disableSlideshowImg":false,"size":{"original":{"width":248,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/096bbc5570301a9041697f9db07b124d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/02wCtZmbpmnmQ_hz5.vnBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/096bbc5570301a9041697f9db07b124d","width":248,"height":78}},"lazy":false},{"type":"text","content":"SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025.","length":313,"tagName":"p"},{"type":"text","content":"“In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter,” said Larry Wood, Chief Executive Officer. “At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commercial organization, established a dedicated launch team to reduce activation variability, and implemented a more disciplined handpiece pricing strategy. Furthermore, we successfully reduced field inventory levels and eliminated end-of-quarter purchasing incentives, which led to a fourth quarter revenue shortfall but improved handpiece average selling price by approximately 5%.”","length":763,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Financial Results","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of $76.4 million for the fourth quarter of 2025, an increase of 12% compared to the prior year period in 2024","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. procedures of approximately 12,200 for the fourth quarter of 2025, an increase of approximately 69% compared to the prior year period","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. handpieces sold of approximately 9,400 for the fourth quarter of 2025, an increase of approximately 7% compared to the prior year pe...